Jessica Bartholomew
Family · Webster, TXNPI 1639732274
Payments from drug & device makers
Across 241 payments — averaging $54.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$8K
- AbbVie$1K
- Madrigal Pharmaceuticals$926
- Takeda Pharmaceuticals U.S.A., Inc.$641
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$334
- Gilead$313
- plus $2K from 24 others
Across 8 payments — averaging $177.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Corcept Therapeutics$1K
What the payments were for
- Consulting fees$1,1559%
- Speaking & faculty fees$5,00838%
- Grants$5004%
- Travel & lodging$1,1539%
- Food & beverage$5,33940%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $7,581 |
| AbbVie | 64 | $1,192 |
| Madrigal Pharmaceuticals | 12 | $926 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $641 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $334 |
| Gilead | 14 | $313 |
| Johnson & Johnson | 17 | $289 |
| Merck | 12 | $264 |
| Pfizer | 7 | $167 |
| Ipsen Biopharmaceuticals, Inc | 7 | $163 |
| Bristol Myers Squibb | 7 | $135 |
| Orphalan Inc | 4 | $126 |
| Corcept Therapeutics | 1 | $124 |
| Redhill Biopharma Inc. | 10 | $121 |
| Ironwood Pharmaceuticals, Inc | 7 | $113 |
| Intercept Pharmaceuticals, Inc. | 3 | $96 |
| Ardelyx, Inc. | 5 | $88 |
| Sanofi | 4 | $86 |
| Exact Sciences | 4 | $70 |
| Nestle Healthcare Nutrition Inc. | 2 | $52 |
| QOL Medical, LLC | 3 | $47 |
| Boehringer Ingelheim | 1 | $47 |
| Braintree Laboratories, Inc. | 2 | $46 |
| Organon | 2 | $32 |
| Fujifilm Healthcare Americas Corporation | 1 | $30 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Evoke Pharma, Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,187 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 30 | $27,256 |
| Mesalamine ErMesalamine | 15 | $7,292 |
| Famotidine | 146 | $2,289 |
| Omeprazole | 159 | $1,455 |
| Pantoprazole Sodium | 46 | $775 |
| Esomeprazole Magnesium | 19 | $579 |
| Sucralfate | 12 | $566 |
| Dicyclomine Hcl | 39 | $522 |
| Ondansetron OdtOndansetron | 13 | $133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,192 | $27,25630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Webster
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.